Teva Pharmaceutical Industries Limited

6 hours ago · reuters.com

Teva to discontinue mid-stage neurodegenerative disorder study

2 days ago · seekingalpha.com

Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and several high-potential pipeline drugs could add $5.5B–$9B in annual peak sales, driving significant revenue growth. Financials are markedly improved: debt halved since 2017, cash balance rising, and revenue rebounding, positioning TEVA for further upside.

3 days ago · fool.com

Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher price levels.

4 days ago · zacks.com

Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

6 days ago · globenewswire.com

Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review

7 days ago · seekingalpha.com

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.

21 days ago · globenewswire.com

TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva's ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.

21 days ago · zacks.com

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

24 days ago · seekingalpha.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

24 days ago · benzinga.com

The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to market Weltruza, a once-monthly subcutaneous injectable for adult patients with schizophrenia.